Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study)

@article{Nomura2018EffectsOS,
  title={Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study)},
  author={Shosaku Nomura and T Taniura and Akira Shouzu and Seitarou Omoto and Masahiko Suzuki and Yoshinori Okuda and Tomoki Ito},
  journal={Vascular Health and Risk Management},
  year={2018},
  volume={14},
  pages={225 - 232}
}
Background The aim was to evaluate the significance of arteriosclerosis obliterans-related biomarkers in patients with type 2 diabetes mellitus (T2DM), and to compare the effects of sarpogrelate, eicosapentaenoic acid (EPA) and pitavastatin on these markers. Patients and methods Seventy-two arteriosclerosis obliterans patients with T2DM were classified into two groups, pitavastatin with either sarpogrelate (PS) or EPA (PE). We observed no differences in all biomarkers between the PS and PE… Expand
Effects of sarpogrelate hydrochloride on peripheral arterial disease
TLDR
Sarpogrelate was effective for improving the symptoms of PAD and showed good tolerability without significant adverse events and the pooled analysis showed that a significant decrease in hsCRP and IL-6 was observed in the sarpog Relate treatment. Expand
Clinical Significance of Endothelin-1 And C Reaction Protein in Restenosis After the Intervention of Lower Extremity Arteriosclerosis Obliterans
TLDR
Serum ET-1 levels were positively correlated with serum CRP levels at both one and three months after surgery, and these might be the risk factors for restenosis of lower extremity arteriosclerosis obliterans patients. Expand
N-3 fatty acids as preventive and therapeutic agents in attenuating PCOS complications
TLDR
N-3 PUFAs are a promising agent in relieving complications associated with PCOS and more trials are warranted to investigate palatable mechanisms for clarifying the metabolic and hormonal effects of these agents in PCOS. Expand
LDL-Cholesterol and Platelets: Insights into Their Interactions in Atherosclerosis
TLDR
The ability to understand and modulate mechanisms governing interactions between LDL-cholesterol and platelets may offer new treatment strategies for atherosclerosis prevention. Expand
Omega-3 fatty acids supplementation in type 2 diabetes : the lack of a sex / gender approach
Many randomized controlled trials indicate that the supplementation with omega-3 polyunsaturated fatty acids (n-3 PUFA) in type 2 diabetes mellitus (T2D) patients can lower glucose levels, as well asExpand
Platelet-Derived Extracellular Vesicles as Target of Antiplatelet Agents. What Is the Evidence?
TLDR
The mechanisms leading to vesiculation in platelets and the pathophysiological processes implicated will be discussed and a summary of the present evidence concerning the effects of antiplatelet agents under experimental conditions and in clinical settings is presented. Expand
Clinical Outcomes of Antiplatelets Combined with Statins in Patients with Ischemic Heart Disease
Clinical Outcomes of Antiplatelets Combined with Statins in Patients with Ischemic Heart Disease Chungsoo Kim, Jimin Lee, Rae Woong Park, and Sukhyang Lee* Department of Biomedical Science, GraduateExpand

References

SHOWING 1-10 OF 55 REFERENCES
The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients
TLDR
It is suggested that pitavastatin possesses an adiponectin-dependent antiatherosclerotic effect, and this drug is able to enhance the anti-platelet effect of EPA, and the combination therapy of pitvastatin and EPA may be beneficial for the prevention of vascular complication in hyperlipidemic patients with type II diabetes. Expand
Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes.
TLDR
It is suggested that EPA possesses an adiponectin-dependent anti-atherosclerotic effect and may be beneficial for the prevention of vascular complications in diabetic patients with high Ang-2 levels. Expand
Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus.
TLDR
It is suggested that pitavastatin possesses an adiponectin-dependent anti-atherosclerotic effect in hyperlipidemic patients with type 2 diabetes in addition to its lowering effects on total cholesterol and LDL-C. Expand
Evaluation of the effectiveness of sarpogrelate on the surrogate markers for macrovascular complications in patients with type 2 diabetes.
TLDR
No significant differences were found between the sarpogrelate group and aspirin group in the clinical indices or in the safety of the subjects related to macrovascular complications during the study period, suggesting that sarpogsrelate may be clinically useful for the primary prevention of macrov vascular complications in patients with type 2 diabetes. Expand
The prognostic value of the serum eicosapentaenoic acid to arachidonic acid ratio in relation to clinical outcomes after endovascular therapy in patients with peripheral artery disease caused by femoropopliteal artery lesions.
TLDR
Lower serum EPA/AA ratios appear to be associated with a greater risk of MALE and death from any cause after EVT in patients with PAD caused by femoropopliteal artery lesions. Expand
Effect of sarpogrelate, a selective 5-HT2A receptor antagonist, on characteristics of coronary artery disease in patients with type 2 diabetes.
TLDR
It is demonstrated that sarpogrelate treatment may decrease coronary artery plaque volume, particularly the noncalcified portion, in patients with diabetes. Expand
Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with Type 2 diabetes mellitus.
TLDR
Findings suggest that in hyperlipidemic patients with Type 2 diabetes, EPA may prevent complications caused by oxidized LDL, E-selectin, and activated platelets or monocytes. Expand
Pitavastatin in the Management of Hypercholesterolemia
TLDR
Pitavastatin has been reported to be associated with a lower frequency of adverse drug effects such as hepatic dysfunction and rhabdomyolysis, therefore, it may be judged as one of the safer among the strong statins. Expand
A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits.
TLDR
Pitavastatin retards the progression of atherosclerosis formation and it improves NO bioavailability by eNOS up-regulation and decrease of O(2)(-). Expand
Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole
TLDR
It is suggested that platelets are activated in ASO patients, and cilostazol is effective to reduce platelet activation, and dipyridamole may potentiate the beneficial effect of cilastazol inASO patients. Expand
...
1
2
3
4
5
...